Pfizer (PFE)

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash deal valued at approximately $6.7 billion. The move, priced at $53.00 per share, marks the culmination of one of the most dramatic corporate turnarounds [...]

As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its aggressive pursuit of treatments for Duchenne Muscular Dystrophy (DMD), the Cambridge-based firm is currently navigating a period of profound transition. After a landmark 2024 [...]

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based pharmaceutical giant is currently navigating one of the most significant strategic transformations in the healthcare sector. At the center of this evolution [...]

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal year. Investors rallied behind the company’s projection of significant revenue growth and resilient earnings, signaling a renewed confidence

Up until recently, the stock has been a chronic underperformer.

Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions.

Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down.

You can get in on these market giants for bargain prices today.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

These companies have impressive track records of navigating the biggest challenges in their industry.

They aren't just "pandemic stocks."

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their options.

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

Pfizer (PFE) shares rise as Talzenna/Xtandi combo hits primary goal in Phase 3 prostate cancer trial. See the full TALAPRO-3 results.

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,

Even on a budget, you can get quality stocks.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ...

As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17, 2026, the Finance sector is projected to report a staggering 19% year-over-year earnings growth,